Quest Magazine

Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015

2015 Becker MD Conference Preview

MDA and Jiffy Lube® Team Up to Support the Fight Against Muscle Disease with Fourth Annual MUSCLE UP!SM Campaign

MDA Unites with the ALS Community as ALS Ice Bucket Challenge Returns

ALS Ice Bucket Challenge Returning This August

Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp

Stores across the Southwest exceed 2015 fundraising goal by nearly $100,000.

PHOENIX, July 7, 2015 — More than 260 Western Refining convenience stores throughout the Southwest, including Giant, Mustang, Sun Dial and Howdy’s, raised more than $524,286 during the Muscular Dystrophy Association's summer camp mobile program, surpassing their original 2015 fundraising goal by nearly $100,000, to help support children fighting muscular dystrophy and related life-threatening diseases that limit muscle strength and mobility.

Sarepta Completes NDA for Eteplirsen and FDA Accepts BioMarin NDA for Drisapersen; Two DMD Treatments on Horizon

Background: On Monday, June 29, BioMarin announced  that the FDA has accepted their New Drug Application (NDA) for drisapersen and Sarepta announced that they have completed their NDA submission for eteplirsen. Both "exon-skipping" drugs target exon 51, and may help up to 13% of Duchenne muscular dystrophy patients.

Supreme Court Upholds Nationwide Health Care Law Subsidies in ACA Ruling

Background: On June 25th, 2015 the United States Supreme Court ruled to uphold nationwide health care law subsidies. Under the Affordable Care Act (ACA), states were tasked with setting up their own exchanges where individuals could purchase healthcare. Some states created exchanges, while others opted to use exchanges run by the federal government. The question at issue in the Supreme Court case King v.

Transitions Center Blog - Trusting the Journey

I still can’t believe I ended up in New York.

Isis Pharmaceuticals Reports Data from ISIS-SMN Rx in Children with Type 2 and 3 SMA